Detalhe da pesquisa
1.
Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728428
2.
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Oncologist
; 27(6): 493-500, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363318
3.
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Oncologist
; 23(8): 943-947, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622697
4.
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.
Biol Blood Marrow Transplant
; 23(6): 870-881, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751936
5.
CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.
Support Care Cancer
; 24(2): 815-822, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26190358
6.
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia.
Clin Cancer Res
; 28(5): 816-820, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753779
7.
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy.
Clin Cancer Res
; 28(12): 2488-2492, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135839
8.
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Haematologica
; 96(3): 432-40, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21134985
9.
Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell-Depleted Human Leukocyte Antigen-Matched Sibling Transplantation.
Biol Blood Marrow Transplant
; 21(5): 954-5, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25711513
10.
Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors.
Clin Hematol Int
; 2(3): 109-116, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595451
11.
Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.
Bone Marrow Transplant
; 50(2): 189-196, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25387087
12.
Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events.
Exp Hematol
; 42(2): 83-9, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24141092